Literature DB >> 10761509

Varicella vaccine.

S A Chartrand1.   

Abstract

Varicella vaccine is safe, effective, and cost-effective in healthy children, adolescents, and adults. Breakthrough cases of MVLS are significantly milder than wild-type varicella infection. No severe adverse events have been reported following vaccination, and the incidence of herpes zoster is less in vaccinees than in individuals who have had natural varicella infections. To date, there is no evidence waning immunity following vaccination. "New and improved" varicella vaccines that may be more effective than the current vaccine and can be stored at refrigerator temperatures may soon become available in the United States.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761509     DOI: 10.1016/s0031-3955(05)70212-1

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  4 in total

Review 1.  [Immunization: Leaps into the future. Foreseeable changes in children's vaccination calendar in the coming years].

Authors:  J Pericas Bosch
Journal:  Aten Primaria       Date:  2003-03-31       Impact factor: 1.137

2.  Varicella vaccination in children with lymphoma and solid tumours.

Authors:  S Emir; M Büyükpamukçu; V Köseoğlu; G Hasçelik; C Akyüz; T Kutluk; A Varan
Journal:  Postgrad Med J       Date:  2006-11       Impact factor: 2.401

3.  Effectiveness of one-dose versus two-dose varicella vaccine in children in Qingdao, China: a matched case-control study.

Authors:  Ping Hu; Feng Yang; Xiaofan Li; Yang Wang; Tingting Xiao; Han Li; Wencheng Wang; Jing Guan; Shanpeng Li
Journal:  Hum Vaccin Immunother       Date:  2021-10-08       Impact factor: 4.526

4.  Economic evaluation of varicella vaccination strategies in Jiangsu province, China: a decision-tree Markov model.

Authors:  Qiang Wang; Shixin Xiu; Liuqing Yang; Jinxin Huang; Tingting Cui; Naiyang Shi; Xuwen Wang; Yuan Shen; Enpin Chen; Bing Lu; Hui Jin; Leesa Lin
Journal:  Hum Vaccin Immunother       Date:  2021-08-06       Impact factor: 4.526

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.